An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome. (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.pupt.2023.102201
PubMed Identifier: 36841351
Publication URI: http://europepmc.org/abstract/MED/36841351
Type: Journal Article/Review
Volume: 79
Parent Publication: Pulmonary pharmacology & therapeutics
ISSN: 1094-5539